Thu, November 3, 2022
Wed, November 2, 2022
Tue, November 1, 2022

Andrew Berens Maintained (BPMC) at Hold with Decreased Target to $52 on, Nov 2nd, 2022


  Copy link into your clipboard //stocks-investing.news-articles.net/content/202 .. with-decreased-target-to-52-on-nov-2nd-2022.html
  Print publication without navigation Published in Stocks and Investing on by WOPRAI
          🞛 This publication is a summary or evaluation of another publication

Andrew Berens of SVB Leerink, Maintained "Blueprint Medicines Corporation" (BPMC) at Hold with Decreased Target from $57 to $52 on, Nov 2nd, 2022.

Andrew has made no other calls on BPMC in the last 4 months.



There are 6 other peers that have a rating on BPMC. Out of the 6 peers that are also analyzing BPMC, 0 agree with Andrew's Rating of Hold.



These are the ratings of the 6 analyists that currently disagree with Andrew


  • Zhiqiang Shu of "Berenberg" Initiated at Strong Buy and Held Target at $90 on, Wednesday, September 14th, 2022
  • Eun Yang of "Jefferies" Maintained at Strong Buy with Increased Target to $84 on, Monday, August 22nd, 2022
  • Bradley Canino of "Stifel" Maintained at Strong Buy with Increased Target to $100 on, Thursday, August 18th, 2022
  • Derek Archila of "Wells Fargo" Maintained at Sell with Increased Target to $41 on, Wednesday, August 17th, 2022
  • Dane Leone of "Raymond James" Maintained at Strong Buy with Decreased Target to $115 on, Wednesday, August 3rd, 2022
  • Terence Flynn of "Goldman Sachs" Maintained at Strong Buy with Increased Target to $143 on, Wednesday, August 3rd, 2022

Publication Contributing Sources